These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21847572)

  • 21. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
    Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
    J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
    J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
    Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
    Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
    Gu H; Luck S; Carroll PV; Powrie J; Chambers J
    Clin Endocrinol (Oxf); 2011 May; 74(5):608-10. PubMed ID: 21198745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
    Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
    Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
    Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The frequency of cardiac valvular regurgitation in Parkinson's disease.
    Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
    Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
    Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
    Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study.
    Ozer N; Yorgun H; Canpolat U; Elibol B
    Anadolu Kardiyol Derg; 2014 Mar; 14(2):121-7. PubMed ID: 24449623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
    Devin JK; Lakhani VT; Byrd BF; Blevins LS
    Endocr Pract; 2008 Sep; 14(6):672-7. PubMed ID: 18996784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
    Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
    J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of iatrogenic severe mitral regurgitation.
    D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
    Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
    Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T; Härtter S; Burger E
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.